INMED PHARMACEUTICALS INC. Accumulated Other Comprehensive Income
INMED PHARMACEUTICALS INC. (INM) had Accumulated Other Comprehensive Income of $128.57 thousand as of 2026-06-30, per its S-4/A filed 2026-09-09.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax · last filed 2026-09-09
- 2026-06-30: Accumulated Other Comprehensive Income (Loss), Net of Tax $128.57K.
- 2026-03-31: Accumulated Other Comprehensive Income (Loss), Net of Tax $128.57K.
- 2025-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax $128.57K.
- 2025-09-30: Accumulated Other Comprehensive Income (Loss), Net of Tax $128.57K.
| Period end | Accumulated Other Comprehensive Income (Loss), Net of Tax |
|---|---|
| 2026-06-30 | $128.57K S-4/A · filed 2026-09-09 |
| 2026-03-31 | $128.57K S-4 · filed 2026-07-02 |
| 2025-12-31 | $128.57K 10-Q · filed 2026-02-11 |
| 2025-09-30 | $128.57K 10-Q · filed 2025-11-06 |
| 2025-06-30 | $128.57K S-4/A · filed 2026-09-09 |
| 2025-03-31 | $128.57K 10-Q · filed 2025-05-12 |
| 2024-12-31 | $128.57K 10-Q · filed 2025-02-12 |
| 2024-09-30 | $128.57K 10-Q · filed 2024-11-14 |
| 2024-06-30 | $128.57K S-4 · filed 2026-07-02 |
| 2023-12-31 | $128.57K 10-Q · filed 2024-02-13 |
| 2023-09-30 | $128.57K 10-Q · filed 2023-11-14 |
| 2023-06-30 | $128.57K 10-K · filed 2024-09-30 |
| 2023-03-31 | $128.57K 10-Q · filed 2023-05-15 |
| 2022-12-31 | $128.57K 10-Q · filed 2023-02-17 |
| 2022-09-30 | $128.57K 10-Q · filed 2022-11-14 |
| 2022-06-30 | $128.57K 10-K · filed 2023-09-29 |
| 2022-03-31 | $128.57K 10-Q · filed 2022-05-13 |
| 2021-12-31 | $128.57K 10-Q · filed 2022-02-14 |
| 2021-09-30 | $128.57K 10-Q · filed 2021-11-10 |
| 2021-06-30 | $128.57K 10-K · filed 2022-09-23 |
| 2021-03-31 | $128.57K 10-Q · filed 2021-05-13 |
| 2020-12-31 | $128.57K 10-Q · filed 2021-02-11 |
| 2020-09-30 | -$172.47K 10-Q · filed 2020-12-17 |
| 2020-06-30 | -$301.87K 10-K · filed 2021-09-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |